Consort Medical

Consort Medical is a global CDMO, providing advanced delivery technologies, formulation and manufacturing solutions, with a focus on nasal. pulmonary and parenteral delivery systems. Its customers include the largest pharmaceutical companies.

Integrating world-class drug delivery device development and manufacture, together with drug API and finished dose formulation and manufacture, within the same group streamlines and accelerates Consort’s pharma customers’ drug route to market.

The Consort group invests in patient- and customer-driven innovation and diversifies into adjacent complementary markets and technologies which leverage its core competencies in drug formulation, manufacturing and delivery.

The company’s King’s Lynn, UK facility produces around 600 million devices per annum. It comprises 35,047 m² of manufacturing space,  21,409 m² of which is clean room. It has 30 fully automated assembly suites and 137 injection mould machines. Around four billion components are assembled annually and 3.3 billion plastic components moulded annually. This output maintains six sigma quality (less than 3.4 defects/million). The Milton Keynes, UK, facility comprises 6,000 m² of manufacturing space of which 2,000 m² is clean room.

Consort Medical was founded in 2007, and comprises two integrated operating divisions:

Bespak Drug Delivery Devices — a global market leader in the development and manufacture of drug delivery devices, providing pharma companies with inhaler and autoinjector technologies and development and manufacturing services.

Aesica Development & Manufacture API & Finished Dose — a leading pharmaceutical CDMO serving pharmaceutical companies with API and finished dose formulation development and manufacturing services.

0

What's this?

SHARE